Biocryst Pharmaceuticals (BCRX) Asset Writedowns and Impairment (2023 - 2026)
Biocryst Pharmaceuticals' (BCRX) quarterly Asset Writedowns and Impairment came in at $74000.0 in Q1 2026, down 64.59% YoY from $209000.0 in Q1 2025, and up 107.01% on a QoQ basis from -$1.1 million in Q4 2025.
Biocryst Pharmaceuticals (BCRX) Asset Writedowns and Impairment (2023 - 2026) Analysis & Trends
Biocryst Pharmaceuticals (BCRX) has 4 years of Asset Writedowns and Impairment data on file, last reported at $74000.0 in Q1 2026.
- Quarterly Asset Writedowns and Impairment fell 64.59% year-over-year to $74000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$135000.0 (down 108.66% YoY) and the FY2024 annual result came in at $1.3 million, down 12.79% from the prior year.
- Asset Writedowns and Impairment rose to $74000.0 in Q1 2026, from -$1.1 million in the prior quarter.
- In the past five years, Asset Writedowns and Impairment ranged from a high of $1.4 million in Q3 2024 to a low of -$1.1 million in Q4 2025.
- A 4-year average of $247666.7 and a median of $52000.0 in 2025 frame the typical range for Asset Writedowns and Impairment.
- The widest YoY moves for Asset Writedowns and Impairment: up 81600.0% in 2025, down 9500.0% in 2025.
- Tracing BCRX's Asset Writedowns and Impairment over 4 years: stood at $1.3 million in 2023, then sank by 100.84% to -$11000.0 in 2024, then tumbled by 9500.0% to -$1.1 million in 2025, then jumped by 107.01% to $74000.0 in 2026.
- The last three Asset Writedowns and Impairment figures came in at $74000.0 (Q1 2026), -$1.1 million (Q4 2025), and $30000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - |
| 10 | Biocryst Pharmaceuticals | 2.46 Bn | 2.11 Bn | 214.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 509,000.00 |
| Jun 30, 2026 | 509,000.00 |
| Mar 31, 2026 | 74,000.00 |
| Mar 31, 2026 | 74,000.00 |
| Dec 31, 2025 | -1.06 Mn |
| Dec 31, 2025 | -1.06 Mn |
| Sep 30, 2025 | 30,000.00 |
| Sep 30, 2025 | 30,000.00 |
| Jun 30, 2025 | 817,000.00 |
| Jun 30, 2025 | 817,000.00 |
| Mar 31, 2025 | 209,000.00 |
| Mar 31, 2025 | 209,000.00 |
| Dec 31, 2024 | -11,000.00 |
| Dec 31, 2024 | -11,000.00 |
| Sep 30, 2024 | 1.36 Mn |
| Sep 30, 2024 | 1.36 Mn |
| Jun 30, 2024 | 1,000.00 |
| Jun 30, 2024 | 1,000.00 |
| Dec 31, 2023 | 1.31 Mn |
| Dec 31, 2023 | 1.31 Mn |